Jim Cramer Slams Political Blocking Of 'LSD-Derived Antidepressants,' Citing Strong Test Data 'Showing They Worked'
Jim Cramer recently hyped up one of his guests in advance of his CNBC show "Mad Money," posting on X that people "will be very interested in MindMed for certain ... LSD," and he made sure his interview did not disappoint. Mind Medicine Inc. (NASDAQ:MNMD) sees a massive market opportunity ahead, citing 21% of U.S. adults with an anxiety disorder, an estimated 4.4% of U.S. adults with attention-deficit/hyperactivity disorder (ADHD) and a $461 billion economic cost from autism spectrum disorder by
Source: yahoo.com